Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.55 |
| ▸ | MPL | P40238 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638419 | 0.85 | NOTUM (0.52) | KMOHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL4870877 | 0.85 | NOTUM (0.47) | KMOMPLHDAC1HDAC8HDAC6 | |
| SCHEMBL12521389 | 0.82 | S1PR1 (0.50) | HDAC1HDAC8HDAC6ALDH1A1RARA | |
| SCHEMBL628001 | 0.81 | LMNA (0.46) | KMOMPL | |
| SCHEMBL2871079 | 0.79 | ALDH1A1 (0.50) | HDAC1HDAC8HDAC6ALDH1A1PTPN1 | |
| SCHEMBL19556359 | 0.78 | KMO (0.53) | KMOHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL30112055 | 0.78 | KMO (0.53) | KMOHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL28038942 | 0.77 | HDAC1 (0.43) | HDAC1HDAC8HDAC6ALDH1A1PTPN1 | |
| SCHEMBL31604686 | 0.77 | KMO (0.54) | KMOHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL2638950 | 0.77 | KMO (0.54) | KMOHDAC1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | KMO 4386/4885MPL 1/4885HDAC1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.